首页> 外文期刊>亚太热带生物医学杂志(英文版) >Anti-inlfammatory and antipyretic properties of kang 601 heji, a traditional Chinese medicine oral liquid dosage form
【24h】

Anti-inlfammatory and antipyretic properties of kang 601 heji, a traditional Chinese medicine oral liquid dosage form

机译:康601合剂(一种中药口服液剂型)的抗炎和解热特性

获取原文
获取原文并翻译 | 示例
           

摘要

Objective:To evaluate the scientific basis for the use of Kang 601 heji (K-601) as an anti-inflammatory and antipyretic agent using appropriate animal models. Methods:Carrageenan-induced rat paw and xylene-induced ear oedemas were models used to investigate anti-inflammatory actions of K-601. Lipopolysaccharide-induced pyrexia model was used to evaluate antipyretic activity in Wistar rats. The anti-inflammatory and antipyretic mechanisms were evaluated by detecting prostaglandins E2, nitric oxide, interleukin-1βand tumor necrosis factor-αlevels using appropriate reagents and ELISA kits. Results:The results revealed that K-601 reduced the level of inflammations in both anti-inflammatory models in a dose-dependent manner. The same was true for the antipyretic model. The possible mechanisms of actions were through the inhibition of prostaglandins E2, interleukin-1β, tumor necrosis factor-αand nitric oxide. Conclusions: K-601 has proven anti-inflammatory and antipyretic actions. The findings provide a scientific basis for the use of K-601 as anti-inflammatory and antipyretic agent in traditional Chinese medicinal practice.
机译:目的:通过适当的动物模型,评价将康601合剂(K-601)用作消炎解热剂的科学依据。 方法:采用角叉菜胶诱导的大鼠爪和二甲苯诱导的耳水肿来研究K-601的抗炎作用。脂多糖诱导的发热模型用于评估Wistar大鼠的退热活性。通过使用适当的试剂和ELISA试剂盒检测前列腺素E2,一氧化氮,白介素-1β和肿瘤坏死因子-α水平来评估抗炎和退热的机制。 结果:结果显示,K-601在两种抗炎模型中均以剂量依赖性方式降低了炎症水平。解热模型也是如此。可能的作用机制是通过抑制前列腺素E2,白介素-1β,肿瘤坏死因子-α和一氧化氮。 结论:K-601具有抗炎和解热作用。这些发现为在传统中医药实践中使用K-601作为消炎解热药提供了科学依据。

著录项

  • 来源
    《亚太热带生物医学杂志(英文版)》 |2015年第11期|872-877|共6页
  • 作者单位

    State Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 24 Tongjiaxiang, Nanjing 210009, China;

    Department of Pharmacology, China Pharmaceutical University, No. 24 Tongjiaxiang, Nanjing 210009, China;

    Joint Key Laboratory for Drug Development, Department of Pharmaceutics, China Pharmaceutical University, No. 24 Tongjiaxiang, Nanjing, China;

    Joint Key Laboratory for Drug Development, Department of Pharmaceutics, China Pharmaceutical University, No. 24 Tongjiaxiang, Nanjing, China;

    Department of Medicinal Chemistry, China Pharmaceutical University, No. 24 Tongjiaxiang, Nanjing 210009, China;

    Joint Key Laboratory for Drug Development, Department of Pharmaceutics, China Pharmaceutical University, No. 24 Tongjiaxiang, Nanjing, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号